SAKAR Share Price Performance
₹362.45
45.95 (14.52%)
Price ₹362.45
Share Price₹362.45
Sakar Healthcare Limited's (NSE:SAKAR) Shares Climb 29% But Its Business Is Yet to Catch Up
Apr 22
Sakar Healthcare Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
SAKAR Community Narratives
There are no narratives available yet.
Sakar Healthcare Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 9.00
- Gross Margin
- 52.87%
- Net Profit Margin
- 10.45%
- Debt/Equity Ratio
- 30.3%
Sakar Healthcare Limited Competitors
Snowflake Analysis
About SAKAR
- Founded
- 2004
- Employees
- 342
- CEO
- WebsiteView website
Sakar Healthcare Limited research, develops, manufactures, and sells pharmaceutical products in India. The company provides liquid orals, cephalosporin tablets, capsules, dry powder syrups and injections, liquid injectable (SVP) in ampoules, vials and lyophilized injections, and oral solid dosages. Its product portfolio consists of formulations in therapeutic areas, such as anti-infective, analgesic, antihistamine, anthelmintic, anti-malarial, antibacterial, vitamins, antifungal, diuretics, oxytocic, antacid, laxative, anticoagulant, anaesthetic, bronchodilator, adrenergic, sedative, anti-inflammatory, antiemetic, anticonvulsant, antipsychotic, antidepressant, and anti-cancer. The company exports its products to Southeast Asia, Asia, Africa-Anglo and Francophone, MENA countries, and the United States. Sakar Healthcare Limited was incorporated in 2004 and is based in Ahmedabad, India.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Indian Market Performance
- 7 Days: 1.5%
- 3 Months: -1.7%
- 1 Year: -4.7%
- Year to Date: 0.7%
The market is up 1.5% over the last week, with the Financials sector leading the way, up 2.3%. In contrast, the market has seen a decline of 4.7% over the last 12 months. Looking forward, earnings are forecast to grow by 16% annually. Market details ›